$DFTX News

Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential

Definium Therapeutics Dosed First Patient In Ascend Phase 3 Study Of DT120 ODT (Lysergide Tartrate) For Major Depressive Disorder, Topline Data From The 12-week Double-blind Period Is Anticipated In 2027

Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript

Piper Sandler Maintains Overweight on Definium Therapeutics, Lowers Price Target to $48

Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight

Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M

Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day Transcript

Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit

Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day - Slideshow

Definium Therapeutics Highlights Advancement Of DT120 ODT Clinical Program And Commercial Strategy In MDD And GAD, With Three Anticipated Topline Readouts In Next Six Months

Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move

Reported Earlier, Definium Therapeutics Issued The Statement Supporting The Newly Signed White House Executive Order Aimed At Accelerating Research, Development, And Responsible Access To Innovative Treatments For Serious Mental Illness, Including Emerging Psychedelic Medical Treatments

Reported Earlier, Definium Therapeutics Issued The Statement Supporting The Newly Signed White House Executive Order Aimed At Accelerating Research, Development, And Responsible Access To Innovative Treatments For Serious Mental Illness, Including Emerging Psychedelic Medical Treatments

Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst

Stifel Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $30

Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $38

Piper Sandler Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $49

Definium Therapeutics Announces Results From Retrospective, Longitudinal Study Published In Journal Of Mood And Anxiety Disorders Examining Real-World Prevalence, Incidence, And Burden Of GAD In US Healthcare System From 2020 To 2023

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum